title: [Therapeutic effect of CY-fTBI and BMM conditioning regimen in the process of allo-HSCT treating Ⅲ,Ⅳ non-Hodgkin lymphoma: 15 years analysis of single-center].
abstract: OBJECTIVE
  To investigate the efficacy of allogeneic hematopoietic stem cell transplantation（allo-HSCT）in the treatment of patients with Ⅲ,Ⅳ non-Hodgkin lymphoma（NHL）, and compared the efficacy between Cy- fractionated to talbody irradiation（fTBI）based conditioning regimen and Maryland, horse flange and mitoxantrone（BMM）.
  
  
  METHODS
  The clinical data of 47 patients with Ⅲ, Ⅳ NHL after allo- HSCT from November 1998 to May 2014 were collected and retrospectively analyzed. To observe the hematopoietic reconstruction recovery after transplantation, cumulative incidence of acute graft- versus- host- disease （aGVHD） and chronic graft- versus- host- disease （cGVHD）, transplantation related mortality （TRM）, recurrence rate （RR）, disease- free survival （DFS）, overall survival（OS）. Compare the efficacy of fTBI and BMM conditioning regimen at the same time.
  
  
  RESULTS
  Neutrophils achieving 0.5×10⁹/L and platelets achieving 50×10⁹/L on day 17 （range, 10- 72） post transplantation. Acute GVHD occurred in 53.19%, among them, grade Ⅰ-Ⅱ occurred in 42.55%, grade Ⅲ-Ⅳ occurred in 10.65%, and cGVHD occurred in 21.28%. 21 patients were alive with a median follow up of 9.7 months（0.2-149.1 months）. Overall survival（OS）was 73.5%, 49.3%, 40.1% respectively in the first, third and fifth year in Cy-fTBI group; in BMM group it was 67.8%, 32.9% and 31.4% respectively, and disease-free survival（DFS）was 65.3%, 45.6%, 30.2% respectively in the first, third and fifth year. In Cy-fTBI group, the recurrence rate（RR）and transplantation related mortality（TRM）in the first year were 18.9%, 23.0% respectively, the third year were 19.5%, 38.3% and the fifth year were 35.2%, 39.2%. In BMM group, RR and TRM in the first year were 27.4%, 24.5% respectively, the third year were 38.9%, 46.4% and the fifth year were 39.2%, 48.2%. However, there was no significant difference in the indicator of OS, DFS, RR, TRM in the two groups.
  
  
  CONCLUSIONS
  Allo-HSCT could make some Ⅲ,Ⅳ NHL patients achieve long-term disease- free survival, but the TRM was still high relatively. Moreover, compared with the program of BMM conditioning regimen, Cy-fTBI might reduce the TRM and RR, meanwhile, increase the DFS and OS. However, due to the small number cases of two groups, there was no statistical significant difference.
authors.affiliation: Institute of Hematology 307 PLA Hospital, Beijing 100071, China.
authors.forename: Ting
authors.initials: T
authors.lastname: Sun
authors.affiliation: Institute of Hematology 307 PLA Hospital, Beijing 100071, China.
authors.forename: Liangding
authors.initials: L
authors.lastname: Hu
authors.affiliation: Institute of Hematology 307 PLA Hospital, Beijing 100071, China.
authors.forename: Min
authors.initials: M
authors.lastname: Jiang
authors.affiliation: Institute of Hematology 307 PLA Hospital, Beijing 100071, China.
authors.forename: Hongmei
authors.initials: H
authors.lastname: Ning
authors.affiliation: Institute of Hematology 307 PLA Hospital, Beijing 100071, China.
authors.forename: Bin
authors.initials: B
authors.lastname: Zhang
authors.affiliation: Institute of Hematology 307 PLA Hospital, Beijing 100071, China.
authors.forename: Jing
authors.initials: J
authors.lastname: Ren
authors.affiliation: Institute of Hematology 307 PLA Hospital, Beijing 100071, China.
authors.forename: Yuhang
authors.initials: Y
authors.lastname: Li
authors.affiliation: Institute of Hematology 307 PLA Hospital, Beijing 100071, China.
authors.forename: Botao
authors.initials: B
authors.lastname: Li
authors.affiliation: Institute of Hematology 307 PLA Hospital, Beijing 100071, China.
authors.forename: Jianlin
authors.initials: J
authors.lastname: Chen
authors.affiliation: Institute of Hematology 307 PLA Hospital, Beijing 100071, China.
authors.forename: Fan
authors.initials: F
authors.lastname: Yang
authors.affiliation: Institute of Hematology 307 PLA Hospital, Beijing 100071, China.
authors.forename: Chen
authors.initials: C
authors.lastname: Xu
authors.affiliation: Institute of Hematology 307 PLA Hospital, Beijing 100071, China.
authors.forename: Jun
authors.initials: J
authors.lastname: Wang
authors.affiliation: Institute of Hematology 307 PLA Hospital, Beijing 100071, China.
authors.forename: Xiao
authors.initials: X
authors.lastname: Lou
authors.affiliation: Institute of Hematology 307 PLA Hospital, Beijing 100071, China.
authors.forename: Jiangwei
authors.initials: J
authors.lastname: Hu
authors.affiliation: Institute of Hematology 307 PLA Hospital, Beijing 100071, China.
authors.forename: Hu
authors.initials: H
authors.lastname: Chen
mesh_terms: D018572:Disease-Free Survival; D006086:Graft vs Host Disease; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000628:therapy*; D009364:Neoplasm Recurrence, Local; D012189:Retrospective Studies; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous